Turn recording back on
Biology of RANK, RANKL, and osteoprotegerin.
Boyce BF, Xing L.
Arthritis Res Ther. 2007;9 Suppl 1:S1. Review.
PMID: 17634140 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
The RANKL/RANK/OPG pathway.
Curr Osteoporos Rep. 2007 Sep;5(3):98-104.
PMID: 17925190 [PubMed - indexed for MEDLINE]
Related Articles
Functions of RANKL/RANK/OPG in bone modeling and remodeling.
Arch Biochem Biophys. 2008 May 15;473(2):139-46. Epub 2008 Mar 25. Review.
PMID: 18395508 [PubMed - indexed for MEDLINE]
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D, Maalouf NM, Sakhaee K.
J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.
PMID: 17895323 [PubMed - indexed for MEDLINE]
Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M.
Expert Rev Anticancer Ther. 2007 Feb;7(2):221-32. Review.
PMID: 17288531 [PubMed - indexed for MEDLINE]
Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T, Feng X.
Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.
PMID: 16945019 [PubMed - indexed for MEDLINE]
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH, Kirschenbaum A, Yao S, Levine AC.
Endocrinology. 2005 Apr;146(4):1991-8. Epub 2004 Dec 23.
PMID: 15618359 [PubMed - indexed for MEDLINE]
[Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans]
Kobayashi Y, Takahashi N.
Clin Calcium. 2008 Feb;18(2):202-9. Review. Japanese.
PMID: 18245890 [PubMed - indexed for MEDLINE]
The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S, Mariette X.
Leuk Lymphoma. 2004 Jun;45(6):1111-8. Review.
PMID: 15359989 [PubMed - indexed for MEDLINE]
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
Schoppet M, Preissner KT, Hofbauer LC.
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. Review.
PMID: 11950689 [PubMed - indexed for MEDLINE]
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.
Horowitz MC, Xi Y, Wilson K, Kacena MA.
Cytokine Growth Factor Rev. 2001 Mar;12(1):9-18. Review.
PMID: 11312114 [PubMed - indexed for MEDLINE]
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.
Prostate. 2008 Jan 1;68(1):92-104.
PMID: 18008334 [PubMed - indexed for MEDLINE]
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F.
Biochim Biophys Acta. 2004 Sep 20;1704(2):49-57. Review.
PMID: 15363860 [PubMed - indexed for MEDLINE]
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC, Schoppet M.
JAMA. 2004 Jul 28;292(4):490-5. Review.
PMID: 15280347 [PubMed - indexed for MEDLINE]
Role of IGF-I signaling in regulating osteoclastogenesis.
Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.
J Bone Miner Res. 2006 Sep;21(9):1350-8.
PMID: 16939393 [PubMed - indexed for MEDLINE]
Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling.
Kim CH, You L, Yellowley CE, Jacobs CR.
Bone. 2006 Nov;39(5):1043-7. Epub 2006 Jul 24.
PMID: 16860618 [PubMed - indexed for MEDLINE]
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S.
Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.
PMID: 17652963 [PubMed - indexed for MEDLINE]
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S, Phillips JS, Sayers J, Croucher PI.
J Biol Chem. 2007 Oct 26;282(43):31601-9. Epub 2007 Aug 15.
PMID: 17702740 [PubMed - indexed for MEDLINE]
Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C, Lorentzon M, Conaway HH, Lerner UH.
Endocrinology. 2006 Jul;147(7):3613-22. Epub 2006 Apr 13.
PMID: 16614077 [PubMed - indexed for MEDLINE]
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P.
Circ Res. 2004 Nov 26;95(11):1046-57. Review.
PMID: 15564564 [PubMed - indexed for MEDLINE]